Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
205 participants
INTERVENTIONAL
2019-03-22
2027-02-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
NCT03317496
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06488716
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756
Study of Avelumab-M3814 Combinations
NCT03724890
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
NCT04305249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Avelumab
Avelumab
Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avelumab
Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Merck Serono Co., Ltd (Japan)
* Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment
* Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists
Exclusion Criteria
* Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients
* Participant has been enrolled in the comparator arm of avelumab parent study
* Participant has been withdrawn from avelumab parent study for any reason
* Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HonorHealth Research Institute
Scottsdale, Arizona, United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
University of California Davis Health System - Comprehensive Cancer Center
Sacramento, California, United States
Providence Medical Foundation
Santa Rosa, California, United States
St Joseph Heritage Healthcare
Santa Rosa, California, United States
Norwalk Hospital - The Whittingham Cancer Center
Norwalk, Connecticut, United States
Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure Coast
Port Saint Lucie, Florida, United States
Northwest Georgia Oncology Centers
Marietta, Georgia, United States
Maryland Oncology Hematology, P.A.
Rockville, Maryland, United States
Michigan State University
Lansing, Michigan, United States
Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
Kansas City Research Institute, LLC - Phase I Unit
Kansas City, Missouri, United States
University of Cincinnati - PARENT
Cincinnati, Ohio, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Oncology/Hematology Care Clinical Trials, LLC
Cincinnati, Ohio, United States
OSU - James Comprehensive Cancer Center
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
Greenville Hospital System University Medical Center (ITOR) - Upstate Affiliate Organization
Greenville, South Carolina, United States
The West Clinic
Germantown, Tennessee, United States
SCRI - Tennessee Oncology
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Oncology Consultants, P.A.
Houston, Texas, United States
Henry Ford Hospital
San Antonio, Texas, United States
University of Vermont Medical Center - Fletcher Allen Gastroenterology
Burlington, Vermont, United States
Instituto Alexander Fleming
Ciudad Autonoma Buenos Aires, , Argentina
Clínica Universitaria Privada Reina Fabiola
Córdoba, , Argentina
Ballarat Health Services
Ballarat, , Australia
Monash Medical Centre Clayton
Clayton, , Australia
Centre Hospitalier de l'Ardenne - Pharmacie
Libramont, , Belgium
Clinique CHC MontLégia
Liège, , Belgium
Hospital de Câncer de Barretos - Fundação Pio XII
Barretos, , Brazil
MHAT for women's health - Nadezhda, OOD
Sofia, , Bulgaria
Nemocnice Rudolfa a Stefanie Benesov a.s. nemocnice Stredoceskeho kraje - parent
Benešov, , Czechia
Masarykuv onkologicky ustav - 300176866 Parent
Brno, , Czechia
CHU Besançon - Hôpital Jean Minjoz - Service d'oncologie Medicale
Besançon, , France
Centre Oscar Lambret - Service d'Oncologie medicale
Lille, , France
ICO - Site Paul Papin - service d'oncologie medicale
Nantes, , France
ICO - Site René Gauducheau - Service d'Oncologie medicale
Nantes, , France
Centre Antoine Lacassagne - Service d'Hématologie Oncologie
Nice, , France
Institut Curie - site de Paris - Service d'Oncologie Médicale
Paris, , France
CHU Bordeaux - Service d'Oncologie Médicale
Pessac, , France
Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires
Pessac, , France
CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale
Poitiers, , France
Centre Paul Strauss - Service de Médecine Oncologique
Strasbourg, , France
Hopital Larrey - Service de Pneumologie et Oncologie Thoracique
Toulouse, , France
Universitaetsklinikum Essen - Westdeutsches Tumorzentrum
Essen, , Germany
Petz Aladar Egyetemi Oktato Korhaz - Pulmonologiai Osztaly
Győr, , Hungary
Zala Varmegyei Szent Rafael Korhaz - Pulmonologiai Osztaly
Zalaegerszeg, , Hungary
Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" - Dipartimento Oncologia
Napoli, , Italy
IOV - Istituto Oncologico Veneto IRCCS
Padua, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Roma, , Italy
Istituto Nazionale Tumori Regina Elena IRCCS - UOC Oncologia Medica A
Roma, , Italy
Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia
Rozzano, , Italy
National Cancer Center Hospital (NCCH)
Chūōku, , Japan
National Cancer Center Hospital - Dept of Gastrointestinal Oncology
Chūōku, , Japan
Osaka Habikino Medical Center - Dept of Pulmonary Oncology
Habikino-shi, , Japan
Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine
Kōtoku, , Japan
Kurume University Hospital - Dept of Lung Cancer Center
Kurume-shi, , Japan
Osaka City General Hospital - Dept of Clinical Oncology
Osaka, , Japan
Tohoku University Hospital
Sendai, , Japan
Osaka University Hospital - Dept of Gastrointestinal Surgery
Suita-shi, , Japan
Health Pharma Professional Research S.A. de C.V.
México, , Mexico
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy - Dept of Lungs and Chest Oncology
Warsaw, , Poland
Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj Napoca - Sectia Radioterapie III
Cluj-Napoca, , Romania
S.C Radiotherapy Center Cluj S.R.L - Parent
Comuna Floresti, , Romania
Institutul Regional de Oncologie Iasi - Sectia Oncologie Medicala
Iași, , Romania
Spitalul Clinic Municipal "Dr. Gavril Curteanu" Oradea - Centrul Oncologie Medicala
Oradea, , Romania
S.C Oncomed S.R.L - Specialitatea Oncologie Medicala
Timișoara, , Romania
RBIH "Kursk regional clinical oncology dispensary" of Kursk Region Healthcare Committee
Kursk, , Russia
SBHI of Novosibirsk region "Novosibirsk Regional Oncological Dispensary"
Novosibirsk, , Russia
BHI of Omsk region "Clinical Oncology Dispensary" - Building #2
Omsk, , Russia
FSBI "National Medical Research Center for Oncology n.a. N.N. Petrov" of the MoH of the RF - Parent
Saint Petersburg, , Russia
LLC "Medical Technologies" - Parent
Saint Petersburg, , Russia
Pavlov First Saint Petersburg State Medical University - PARENT
Saint Petersburg, , Russia
Chungbuk National University Hospital
Cheongju-si, , South Korea
Chonnam National University Hwasun Hospital
Daejeon, , South Korea
National Cancer Center
Goyang, , South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, , South Korea
Hospital de la Santa Creu i Sant Pau - Dept of Oncology
Barcelona, , Spain
Hospital Universitari Vall d'Hebron - Oncology Dept.
Barcelona, , Spain
Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica
Madrid, , Spain
Hospital de Mataro - Servicio de Oncologia Medica
Mataró, , Spain
Songklanagarind Hospital - Department of Medicine
Songkhla, , Thailand
Adana City Hospital - Parent Account
Adana, , Turkey (Türkiye)
Ankara University Medical Faculty - Medical Oncology
Ankara, , Turkey (Türkiye)
Hacettepe University Medical Faculty - Oncology
Ankara, , Turkey (Türkiye)
Goztepe Prof. Dr. Suleyman Yalcin City Hospital - Medical Oncology
Istanbul, , Turkey (Türkiye)
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty - Medical Oncology
Istanbul, , Turkey (Türkiye)
Medipol University Medical Faculty - Parent
Istanbul, , Turkey (Türkiye)
Ege University Medical Faculty - PARENT
Izmir, , Turkey (Türkiye)
Mersin University Medical Faculty - Medical Oncology
Mersin, , Turkey (Türkiye)
CNE KHERSON REG ONCOLOGICAL DISPENSARY OF KHERSON RC - Day Hosp of Polycl with Outpatient Chemoth Room
Kherson, , Ukraine
BP Medical
Vinnytsia, , Ukraine
Podilskyi Regional Oncological Center - Dept of Chemotherapy
Vinnytsia, , Ukraine
Sarah Cannon Research Institute UK
London, , United Kingdom
Mount Vernon Cancer Centre
Northwood, , United Kingdom
Derriford Hospital - Dept of Oncology Clinical Trials
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
US Medical Information website, Medical Resources
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-003711-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2024-514274-46-00
Identifier Type: CTIS
Identifier Source: secondary_id
MS100070_0176
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.